tbuckley/cabot-search huggingface dataset:
Abstract 11328: Impact of Periodontitis on Long-term Clinical Outcomes in Patients With Atrial Fibrillation
Authors: Sung Il Im
Journal: Circulation (2016)

Introduction: Relationship between atrial fibrillation (AF) and inflammation was shown in previous studies. Hypothesis: However, there was limited data about the association between the periodontitis and atrial fibrillation in the long-term follow up. The aim of this study was to evaluate the impact of periodontitis on long-term clinical outcomes in patients with AF. Methods: The Kosin University echocardiography, electrocardiogram (ECG) and periodontitis database were reviewed from 2010 to 2015 to identify patients with AF and periodontitis. Patients were followed for a median of 2.1 years and were divided into two groups according to the absence or presence of periodontitis in patients with AF. Results: Among 227 patients with AF, 47 (20.7%) patients had periodontitis. Total any event rates were significantly higher in patients with periodontitis compared to those without periodontitis ( P &lt;0.001). Arrhythmias including AF, atrial tachycardia, atrial premature beat, ventricular tachycardia, and ventricular premature beat also occurred in 36 patients, with a significantly higher incidence in patients with periodontitis than in those without periodontitis ( P &lt;0.001). In univariate analysis, age, CHA 2 DS 2 VASc, Left atrial volume index (LAVI) and periodontitis were significantly associated with arrhythmic events and total any events including bleeding events, thromboembolic events, arrhythmic events, re-hospitalizations and mortality. In multivariate analysis, LAVI ( P =0.005) and periodontitis ( P &lt;0.001) were independent risk factors for arrhythmic events and periodontitis ( P &lt;0.001) for total any events at the long-term follow-up. Conclusions: The patients with periodontitis were associated with higher total any events and arrhythmic events, suggesting more intensive medical therapy with close clinical follow-up will be required.
Delayed Adjuvant Chemotherapy and Survival After Lung Cancer Surgery
Authors: Samer Al Hadidi
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
PREDICT, a study evaluating baseline (BL) disease characteristics predictive of a positive imaging study for distant metastases in patients (pts) with castration-resistant prostate cancer (CRPC): Preliminary data.
Authors: Neal D. Shore, Raoul S. Concepcion, Matthew Raymond Smith, Christopher Michael Pieczonka, Son Nguyen, Laurence H. Belkoff, Robert Firlit, Candice McCoy, Todd DeVries, Stephen J. Freedland
Journal: Journal of Clinical Oncology (2015)

e16028 Background: At diagnosis, most men with PC have localized disease with no distant metastases (M0) or regional lymphadenopathy (N0). After therapy, 20–40% of men have biochemical recurrence, often treated with androgen deprivation therapy (ADT). Other pts may receive primary ADT for N0/M0 disease. Both groups are at risk of CRPC, ie rising prostate-specific antigen (PSA) in absence of radiographic proven metastatic disease (M0). Metrics predicting a positive imaging test for men presumed M0 CRPC are not universally accepted/implemented. PREDICT’s primary objective is to evaluate characteristics predictive of a BL imaging study positive for distant metastases (M1) in men thought to have M0 CRPC. Methods: Eligible men have M0 CRPC, no prior M1, no imaging in > 3 mos and are classified as M0 or M1 based on BL bone and soft tissue imaging. Pts will be followed for 3 (M0) to 5 (M1) yrs after last pt registration. Results: Sixty-five men have BL scans and interim descriptive BL data. At BL, 18/65 (28%) men were M1; 37 men had Tc99 bone scintigraphy and 28 had NaF PET/CT scans to assess bone metastases (scan type at Investigator discretion). Scans were positive for bone metastases in 4/37 (10.8%) Tc99 scans vs 9/28 (32.1%) NaF PET/CT (p = 0.06). Five men had only soft tissue lesions. The M1 group, vs M0 group, were older (84 vs 79 yrs), more likely to have Eastern Cooperative Oncology Group (ECOG) performance status > 0 (44 vs 32%), a Gleason score ≥ 8 (44 vs 34%), and had a shorter time from diagnosis to study entry (6.6 vs 12.6 yrs). BL median laboratory parameters were higher in the M1 vs M0 group for serum PSA (10.1 vs 4.8 ng/mL), alkaline phosphatase (88 vs 73 U/L), lactate dehydrogenase (200 vs 186 U/L), and serum prostatic acid phosphatase (2.6 vs 1.2 ng/mL). Conclusions: These real-world, preliminary data from a small group of men with presumed M0 CRPC suggest that undetected M1 is common, as is M1 occurrence in soft tissues only. M1 detection appeared higher in the small number of men having a NaF PET/CT scan. This study will contribute to clinical guidance on optimal timing, frequency, and imaging study modality for detecting M1 CRPC. Clinical trial information: NCT01981109.
Doxycycline induces bone repair and changes in Wnt signalling
Authors: Kátia do Nascimento Gomes, Ana Paula Negreiros Nunes Alves, Paula Góes Pinheiro Dutra, Glauce Socorro de Barros Viana
Journal: International Journal of Oral Science (2017)

Doxycycline (DOX) exhibits anti-inflammatory and MMP inhibitory properties. The objectives of this study were to evaluate the effects of DOX on alveolar bone repair. Controls (CTL) and DOX-treated (10 and 25 mg·kg−1) molars were extracted, and rats were killed 7 or 14 days later. The maxillae were processed and subjected to histological and immunohistochemical assays. Hematoxylin-eosin staining (7th day) revealed inflammation in the CTL group that was partly reversed after DOX treatment. On the 14th day, the CTL group exhibited bone neoformation, conjunctive tissue, re-epithelization and the absence of inflammatory infiltrate. DOX-treated groups exhibited complete re-epithelization, tissue remodelling and almost no inflammation. Picrosirius red staining in the DOX10 group (7th and 14th days) revealed an increased percentage of type I and III collagen fibres compared with the CTL and DOX25 groups. The DOX10 and DOX25 groups exhibited increases in osteoblasts on the 7th and 14th days. However, there were fewer osteoclasts in the DOX10 and DOX25 groups on the 7th and 14th days. Wnt-10b-immunopositive cells increased by 130% and 150% on the 7th and 14th days, respectively, in DOX-treated groups compared with the CTL group. On the 7th day, Dickkopf (Dkk)-1 immunostaining was decreased by 63% and 46% in the DOX10 and DOX25 groups, respectively. On the 14th day, 69% and 42% decreases in immunopositive cells were observed in the DOX10 and DOX25 groups, respectively, compared with the CTL group. By increasing osteoblasts, decreasing osteoclasts, activating Wnt 10b and neutralising Dkk, DOX is a potential candidate for bone repair in periodontal diseases. An antibiotic commonly used to treat bacterial infections helps promote healing in the jawbones of rats. Glauce Viana and colleagues from the Federal University of Ceará in Fortaleza, Brazil, extracted upper molar teeth from rats and then treated the animals with either the antibiotic drug doxycycline or a saline control. After seven days, the rats that received doxycycline had less inflammation in their tooth sockets than the controls, and after 14 days, more signs of successful wound closure. Looking closely at the cells in the repaired bone in the antibiotic-treated rats, the researchers saw more bone-forming osteoblast cells, fewer bone-resorbing osteoclast cells and greater activity of a signaling pathway known to improve bone healing. The authors suggest the drug should now be tested in people suffering from periodontal disease.
Utility and limitations of exome sequencing in the molecular diagnosis of pediatric inherited platelet disorders
Authors: Edward J. Romasko, Batsal Devkota, Sawona Biswas, Vijayakumar Jayaraman, Ramakrishnan Rajagopalan, Matthew C. Dulik, Christopher S. Thom, Jiwon Choi, Sowmya Jairam, Maria I. Scarano, Ian D. Krantz, Nancy B. Spinner, Laura K. Conlin, Michele P. Lambert
Journal: American Journal of Hematology (2017)

Inherited platelet disorders (IPD) are a heterogeneous group of rare disorders that affect platelet number and function and often predispose to other significant medical complications. In spite of the identification of over 50 IPD disease-associated genes, a molecular diagnosis is only identified in a minority (10%) of affected patients without a clinically suspected etiology. We studied a cohort of 21 pediatric patients with suspected IPDs by exome sequencing (ES) to: (1) examine the performance of the exome test for IPD genes, (2) determine if this exome-wide diagnostic test provided a higher diagnostic yield than has been previously reported, (3) to evaluate the frequency of variants of uncertain significance identified, and (4) to identify candidate variants for functional evaluation in patients with an uncertain or negative diagnosis. We established a high priority gene list of 53 genes, evaluated exome capture kit performance, and determined the coverage for these genes and disease-related variants. We identified likely disease causing variants in 5 of the 21 probands (23.8%) and variants of uncertain significance in 52% of patients studied. In conclusion, ES has the potential to molecularly diagnose causes of IPD, and to identify candidate genes for functional evaluation. Robust exome sequencing also requires that coverage of genes known to be associated with clinical findings of interest need to be carefully examined and supplemented if necessary. Clinicians who undertake ES should understand the limitations of the test and the full significance of results that may be returned.
Survival of acute myelogenous leukemia patients who served in the military compared to civilians.
Authors: Mohamad Osama Khawandanah, Shawn Chaudry, Jordan Morton, Gabriel Vidal, Michael Machiorlatti, Summer Frank, Sara Vesely, Mohamad Ali Cherry
Journal: Journal of Clinical Oncology (2016)

e18524 Background: Many factors have been found to impact treatment outcomes of acute myeloid leukemia (AML) patients (pts) including age at diagnosis, race, cytogenetic risk, and WBC count on presentation. Although these clinical and demographic features might be easily identified, models predicting treatment outcomes for AML have not been rigorously explored. This study aims to investigate how socioeconomic factors with particular focus on the military status may impact treatment outcomes of patients with newly diagnosed AML. Methods: We retrospectively analyzed all pts diagnosed with AML and treated at the University of Oklahoma over 18 years of age from January 2000 to June 2012. 215 AML pts were identified. The AML patient, or next of kin, was contacted and asked to complete a telephone questionnaire with 11 questions. Verbal consent was recorded. Study protocol was approved by local IRB. 181 pts or next of kin responded to questions regarding marital status, family support, difficulty with transportation, renting hotel/motel for treatment, car ownership, and level of stress during treatment. Results: Majority of pts were males (61%), married (45%), achieved CR (64%) with median age of 52 years. The median OS was 27 months. Most pts reported good family support (65%), having not served in the military (94%), or having difficulty with travel (73%). After adjusting for age and cytogenetic risk, military status was marginally associated with OS (p-value = 0.0548). The hazard of death for those in the military is 2.36 times higher for patients with AML relative to civilians (95% CI: 0.98, 5.69). Pts who report difficulty with transportation have 0.35 times the odds of achieving CR relative to those who don’t report this difficulty (95% CI: 0.13, 0.97). Married pts have 1.35 times the odds of achieving CR compared to those who are widowed (95% CI: 0.32, 5.68). Conclusions: AML pts who served in the military may have lower OS compared to those who have not. This finding may be related to unmeasured exposure to potential carcinogens. We also found that pts who reported difficulty with transportation have lower rates of CR. Further exploration of these variables and their impact on AML outcomes is warranted in the future.
Response-adapted therapy for limited stage diffuse large B-cell lymphoma based on interim PET-CT: preliminary results of a phase 2 study
Authors: Fangfang Lv, Zuguang Xia, Kai Xue, Qunling Zhang, Dongmei Ji, Junning Cao, Xiaonan Hong, Ye Guo
Journal: The Lancet Oncology (2017)
FOLFIRINOX in first-line metastatic pancreatic cancer regimen (FLMPC): What profile of patients take a real advantage? Real world cohort from cancer observatory from Brittany and Pays de la Loire areas.
Authors: Jean-Philippe Metges, Jean François Ramée, Roger Faroux, Jean-Yves Douillard, Marc Porneuf, Isabelle Cumin, Pierre-Luc Etienne, Alain Gourlaouen, Guillaume Geslin, Nacredine Achour, Patrick Soulie, Gerard Le Bihan, Catherine Le Roux, Laurent Miglianico, Philippe Deguiral, Christian Riche, Fanny Marhuenda, Delphine Deniel Lagadec, Loic Campion, Francoise Grude
Journal: Journal of Clinical Oncology (2014)

e15204 Background: Folfirinox is one of the gold standard in metastatic pancreatic cancer as first-line therapy for patients with PS 0-1, good haematological and renal function and a subnormal bilirubin level. Pending approval, this treatment has been allowed in Brittany (B) and Pays de la Loire (PL) respecting these criteria. Modified regimen is also proposed to patients without a real evaluation in term of objective response (OR), progression free survival (PFS) and overall survival (OS). Methods: Observatory of Cancer B/PL is a network of 50 private/public cancer centers focused on good practice about cancer drugs. Our aim is to evaluate the use of Folfirinox without or with modifications as First Line Metastatic Pancreatic Cancer regimen between July 2010 and June 2013 in B/PL. Sex, age, successive chemotherapeutic regimens, toxicities, response rate, PFS and OS have been studied. Results: Data from 264 patients were analyzed. Group 1: 238 patients with all Conroy's criteria (Conroy et al, 2011). Group 2: 26 patients with one or more Conroy's criteria not respected. The median number of treatment courses was 9 [1-24]. OR was observed in 98 patients from group 1 (41%) and 4 patients from group 2 (15%). Full Dose Folfirinox regimen (FDF) was given in 45 patients (19%) and 6 patients (23%) during all courses. At first course, Modified Folfirinox (MDF) was performed in 41% and 50%. After first course, 40% and 27% had a dose adjustment and 30 % had one or more dose delays. .Median PFS and OS were respectively 6.54 months IC95% [5.98-7.29] and 10.91 months IC95% [8.94-12.02] for group 1 and 4.14 months IC95% [1.68-6.21] and 7.00 months IC95% [4.01-11.20] for group 2. Conclusions: Non respect of Conroy's criteria leds to a statistically decrease in term of OR, PFS and OS. The use of Full dose Folfirinox regimen is effective in only 19% of the patients. A comparison between FDF at first course and MDF subgroup from Group 1 and Group 2 patients in term of OR, PFS and OS will be shown during the meeting.
Reply to ‘Risk of malignancies associated with ustekinumab’
Authors: B. Nardone, D.P. West
Journal: British Journal of Dermatology (2017)

For, “Malignancies and ustekinumab: an analysis of the FDA Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database” [1], Greenspan et al. [2] raise the issue about adding to the understanding of the drug safety profile, underscoring the need for robust evidence in determination of incidence rate and true risk. In response to this important issue, it must be emphasized to the reader that the approach to pharmacovigilance that we have utilized in this instance is not designed to address causality and/or risk quantification, but rather this widely accepted approach focuses on detection of safety signal.

This article is protected by copyright. All rights reserved.
Talking to Machines About Personal Mental Health Problems
Authors: Adam S. Miner, Arnold Milstein, Jefferey T. Hancock
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is the UK’s 2017 drug strategy fit for purpose?
Authors: Chris Ford, David Nutt, Niamh Eastwood, Deborah Gold, John Jolly, Fionnuala Murphy, Kate Halliday, Jamie Bridge
Journal: BMJ (2017)

The UK government has published its 2017 drug strategy,12 and we are greatly concerned at the lack of focus on harm reduction—an evidence based response that protects people and saves lives—at a time when drug related deaths are the highest on record. The government acknowledges in the strategy that the rise in drug related deaths is “dramatic and …
Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma
Authors: Pieter-Paul Hekking, Matthew J. Loza, Stelios Pavlidis, Bertrand De Meulder, Diane Lefaudeux, Frederic Baribaud, Charles Auffray, Ariane H. Wagener, Paul Brinkman, René Lutter, Aruna T. Bansal, Ana R. Sousa, Stewart A. Bates, Ioannis Pandis, Louise J. Fleming, Dominick E. Shaw, Stephen J. Fowler, Yike Guo, Andrea Meiser, Kai Sun, Julie Corfield, Peter Howarth, Elisabeth H. Bel, Ian M. Adcock, Kian Fan Chung, Ratko Djukanovic, Peter J. Sterk
Journal: European Respiratory Journal (2017)

A proportion of severe asthma patients suffers from persistent airflow limitation (PAL), often associated with more symptoms and exacerbations. Little is known about the underlying mechanisms. Here, our aim was to discover unexplored potential mechanisms using Gene Set Variation Analysis (GSVA), a sensitive technique that can detect underlying pathways in heterogeneous samples. Severe asthma patients from the U-BIOPRED cohort with PAL (post-bronchodilator forced expiratory volume in 1 s/forced vital capacity ratio below the lower limit of normal) were compared with those without PAL. Gene expression was assessed on the total RNA of sputum cells, nasal brushings, and endobronchial brushings and biopsies. GSVA was applied to identify differentially enriched predefined gene signatures based on all available gene expression publications and data on airways disease. Differentially enriched gene signatures were identified in nasal brushings (n=1), sputum (n=9), bronchial brushings (n=1) and bronchial biopsies (n=4) that were associated with response to inhaled steroids, eosinophils, interleukin-13, interferon-α, specific CD4<sup>+</sup> T-cells and airway remodelling. PAL in severe asthma has distinguishable underlying gene networks that are associated with treatment, inflammatory pathways and airway remodelling. These findings point towards targets for the therapy of PAL in severe asthma.
Discussion on “Opening pressures and atelectrauma in acute respiratory distress syndrome”
Authors: Meiling Dong, Yongfang Zhou, Yan Kang, M. Cressoni, D. Chiumello, L. Gattinoni
Journal: Intensive Care Medicine (2017)

Recently, we read the article in your journal by Cressoni et al. [1] which found that the prerequisites of the open lung strategy are not satisfied and higher pressures are needed.We congratulate them on their results and good writing.However, we feel some points merit a precise discussion.First, the lung recruitment has many benefits, but it also has complications such as hypotension, arrhythmias, desaturation, and barotrauma.Research shows that volutrauma is associated with a higher risk for ventilator-induced lung injury (VILI) and furthermore higher lung inflammation than atelectrauma [2]; and Tonetti et al. [3], on re-analyzing the data [2], suggested that compared to the atelectrauma group, the volutrauma was ventilated with double the mechanical power (same tidal volume, respiratory rate, and driving pressure, but different PEEP).PEEP may prevent VILI by reducing the dynamic stress/strain.However, in the absence of consistent lung recruitability, PEEP may solely increase the end-inspiratory stress/strain with no benefit.Those increased stress/strains may be above the VILI threshold.Hence, we think it [1] may mislead the reader in clinical work.Another problem is why choose extracorporeal membrane oxygenation (ECMO) patients?Many studies suggested resting the lung during ECMO by limiting plateau pressure to less than 30 cmH 2 O, and using a moderate/ high PEEP (10-14 cmH 2 O).Although there are no large randomized studies focused on mechanical ventilator settings during ECMO in severe ARDS, we think it is reasonable, at this time, to perform an ultra-protective ventilation strategy which limits tidal volume to less than 4 ml/kg PBW, targets a very low plateau pressure (less than 25 cmH 2 O), and provides PEEP for lung recruitment.So we believe the choice of higher pressure in ECMO patients is still debatable.
Herbert Kahler 1896–1962
Journal: JNCI Journal of the National Cancer Institute (1962)

Herbert Kahler 1896–1962 Get access Harold W. Chalkley Harold W. Chalkley Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 29, Issue 2, August 1962, Pages V–VIII, https://doi.org/10.1093/jnci/29.2.V Published: 01 August 1962